Influence of GST Gene Polymorphisms on the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 8, 2011, Pages 1222-1230

  Kim, Sung Doo ^a   Lee, Je Hwan ^a   Hur, Eun Hye ^a   Lee, Jung Hee ^a   Kim, Dae Young ^a   Lim, Sung Nam ^a   Choi, Yunsuk ^a   Lim, Hyeong Seok ^a   Bae, Kyun Seop ^a   Noh, Gyu Jeong ^a   Yun, Sung Cheol ^a   Han, Sang Beom ^b   Lee, Kyoo Hyung ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Chung Ang University   (South Korea)

Author keywords

Busulfan; Glutathione S Transferase; Hematopoietic cell transplantation; Pharmacogenetics; Pharmacokinetics

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; ISOENZYME; PHENYTOIN; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CHRONIC MYELOID LEUKEMIA; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE DISORDER; NULL ALLELE; SEIZURE;

ADOLESCENT; ADULT; ALKYLATING AGENTS; BUSULFAN; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTATHIONE TRANSFERASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; ISOENZYMES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TRANSPLANTATION CONDITIONING; VIDARABINE; YOUNG ADULT;

EID: 79960283058     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.12.708     Document Type: Article

References (53)

1. Brochstein J.A., Kernan N.A., Groshen S., et al. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med 1987, 317:1618-1624.
2. Michel G., Gluckman E., Esperou-Bourdeau H., et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation-a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 1994, 12:1217-1222.
3. Santos G.W., Tutschka P.J., Brookmeyer R., et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983, 309:1347-1353.
4. Tutschka P.J., Copelan E.A., Klein J.P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987, 70:1382-1388.
5. Copelan E.A., Deeg H.J. Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 1992, 80:1648-1658.
6. Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995, 16:31-42.
7. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997, 89:3055-3060.
8. Dix S.P., Wingard J.R., Mullins R.E., et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996, 17:225-230.
9. Vassal G. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review). Anticancer Res 1994, 14:2363-2370.
10. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000, 6:548-554.
11. Andersson B.S., Thall P.F., Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002, 8:477-485.
12. Nath C.E., Earl J.W., Pati N., Stephen K., Shaw P.J. Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients. Br J Clin Pharmacol 2008, 66:50-59.
13. Leger F., Nguyen L., Puozzo C. Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients. Eur J Clin Pharmacol 2009, 65:903-911.
14. Gibbs J.P., Gooley T., Corneau B., et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999, 93:4436-4440.
15. McCune J.S., Holmberg L.A. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol 2009, 5:957-969.
16. Petros W.P., Evans W.E. Anticancer agents. Applied Pharmacokinetics & Pharmacodynamics Principles of Therapeutic Drug Monitoring 2006, Lippincott Williams & Wilkins, Baltimore, MD. M.E. Burton, L.M. Shaw, J.J. Schentag, W.E. Evans (Eds.).
17. Czerwinski M., Gibbs J.P., Slattery J.T. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 1996, 24:1015-1019.
18. Gibbs J.P., Czerwinski M., Slattery J.T. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res 1996, 56:3678-3681.
19. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005, 45:51-88.
20. Strange R.C., Spiteri M.A., Ramachandran S., Fryer A.A. Glutathione-S-transferase family of enzymes. Mutat Res 2001, 482:21-26.
21. Matsuno K., Kubota T., Matsukura Y., Ishikawa H., Iga T. Genetic analysis of glutathione S-transferase A1 and T1 polymorphisms in a Japanese population. Clin Chem Lab Med 2004, 42:560-562.
22. Hayes J.D., Strange R.C. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000, 61:154-166.
23. Abei M., Harada S., Tanaka N., McNeil M., Osuga T. Immunohistochemical localization of human liver glutathione S-transferase (GST) isozymes with special reference to polymorphic GST1. Biochim Biophys Acta 1989, 995:279-284.
24. van Bladeren P.J. Glutathione conjugation as a bioactivation reaction. Chem Biol Interact 2000, 129:61-76.
25. Luckey S.W., Petersen D.R. Metabolism of 4-hydroxynonenal by rat Kupffer cells. Arch Biochem Biophys 2001, 389:77-83.
26. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res 2000, 463:247-283.
27. Poonkuzhali B., Chandy M., Srivastava A., Dennison D., Krishnamoorthy R. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos 2001, 29:264-267.
28. Gaziev J., Nguyen L., Puozzo C., et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood 2010, 115:4597-4604.
29. Johnson L., Orchard P.J., Baker K.S., et al. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J Clin Pharmacol 2008, 48:1052-1062.
30. Zwaveling J., Press R.R., Bredius R.G., et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther Drug Monit 2008, 30:504-510.
31. Ansari M, Lauzon-Joset JF, Vachon MF, et al. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant;45:261-267.
32. Kusama M., Kubota T., Matsukura Y., et al. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta 2006, 368:93-98.
33. Gaziev J., Nguyen L., Puozzo C., et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood 2010, 115:4597-4604.
34. Ansari M., Lauzon-Joset J.F., Vachon M.F., et al. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant 2010, 45:261-267.
35. Voso M.T., D'Alo F., Putzulu R., et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 2002, 100:2703-2707.
36. Takanashi M., Morimoto A., Yagi T., et al. Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia. Haematologica 2003, 88:1238-1244.
37. Howells R.E., Redman C.W., Dhar K.K., et al. Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin Cancer Res 1998, 4:2439-2445.
38. Lucena M.I., Andrade R.J., Martinez C., et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008, 48:588-596.
39. Ryu S.G., Lee J.H., Choi S.J., et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007, 13:1095-1105.
40. Coles B.F., Morel F., Rauch C., et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 2001, 11:663-669.
41. Ping J., Wang H., Huang M., Liu Z.S. Genetic analysis of glutathione S-transferase A1 polymorphism in the Chinese population and the influence of genotype on enzymatic properties. Toxicol Sci 2006, 89:438-443.
42. Lee H.S., Lee J.H., Hur E.H., et al. Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics. Leuk Res 2009, 33:426-433.
43. Evans W.E., McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003, 348:538-549.
44. Evans W.E., Johnson J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001, 2:9-39.
45. Ufer M., Dilger K., Leschhorn L., et al. Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clin Pharmacol Ther 2008, 84:43-46.
46. Garte S., Gaspari L., Alexandrie A.K., et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001, 10:1239-1248.
47. Cho H.J., Lee S.Y., Ki C.S., Kim J.W. GSTM1, GSTT1 and GSTP1 polymorphisms in the Korean population. J Korean Med Sci 2005, 20:1089-1092.
48. Lin H.J., Han C.Y., Bernstein D.A., Hsiao W., Lin B.K., Hardy S. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 1994, 15:1077-1081.
49. Rebbeck T.R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997, 6:733-743.
50. Nelson H.H., Wiencke J.K., Christiani D.C., et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 1995, 16:1243-1245.
51. Kim I., Keam B., Lee K.H., et al. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Clin Transplant 2007, 21:207-213.
52. Romero R.Z., Morales R., Garcia F., et al. Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. Oncol Rep 2006, 16:497-503.
53. Palma S., Cornetta T., Padua L., et al. Influence of glutathione S-transferase polymorphisms on genotoxic effects induced by tobacco smoke. Mutat Res 2007, 633:1-12.